The feasibility of PETHEMA ALL-96 regimen on treatment of patients with acute lymphoid leukemia

Abstract

Background: Asparaginase-based treatment regimen for acute lymphocytic leukemia (ALL) is considered as feasible, but there is still a lack of data. In this study, considering the results of other regimen that were not optimum in previous studies. Here, we aimed to investigate the feasibility of PETHEMA ALL-96 treatment regimen.Materials and Methods: This is a retrospective feasibility study that was performed in 2019-2021 on 13 patients diagnosed with B-cell ALL. Patients were treated by PETHEMA ALL-96 regimen during induction, consolidation, reinduction, and maintenance phases. Patients were followed for 2 years after initiation of PETHEMA ALL-96 regimen for disease-free survival (DFS) and overall survival (OS) of all patients were evaluated after 2 years.Results: Data of 11 patients were analyzed. Within 28 days after treatments, all patients (100) had no blasts in the bone marrow that was considered as complete remission (CR). The CR rate was 100 within 6 months and 12 months and 81.8 within 2 years after the treatments. Evaluation of OS, CR, and DFS regarding 6, 12, and 24 months showed 100 for all items after 6 and 12 months. After 24 months, the CR was 90.9, the OS was 81.8 and the DFS was 90.9. None of the patients died during the induction phase and during the 12 months study. No side effects were observed.Conclusion: The PETHEMA ALL-96 had high feasibility and survival rates with no side effects during the study course. It is believed that PETHEMA ALL-96 regimen has beneficial outcomes in young patients with ALL.